Bayhealth Partnership Connects Genomic Expertise to Improve Cancer Treatment and Research Access

Bayhealth is advancing its commitment to cutting-edge cancer care through a new collaboration with The Jackson Laboratory (JAX) and N-Power Medicine. This partnership brings an integrated molecular tumor board program to the Bayhealth Cancer Institute, strengthening its precision oncology capabilities and enhancing treatment options for patients across central and southern Delaware.

At the heart of this initiative is Bayhealth’s focus on empowering its oncology team with deeper genomic expertise. Through JAX’s Maine Cancer Genomics Initiative (MCGI), Bayhealth clinicians will participate in virtual genomic tumor boards where multidisciplinary experts analyze tumor sequencing data alongside each patient’s clinical history. These sessions help translate complex molecular findings into personalized treatment strategies, enabling Bayhealth providers to make more informed, confident care decisions.

Complementing this expertise, N-Power Medicine contributes a prospective, point-of-care data platform that transforms everyday clinical care into high-quality, research-ready data. For Bayhealth patients, this means expanded access not only to targeted therapies but also to clinical trials and emerging research opportunities — options that are often less accessible in community care settings.

This collaboration positions Bayhealth as a leader in bringing advanced precision oncology to a community-based environment. By integrating expert genomic interpretation with real-time clinical data, Bayhealth is improving how cancer is treated locally while opening doors to innovative therapies and research participation.

Ultimately, Bayhealth’s partnership with JAX and N-Power Medicine reflects a broader mission: ensuring that patients receive the most advanced, personalized cancer care possible — close to home. Learn more about Bayhealth cancer treatments at Bayhealth.org/Cancer. Learn more about the partnership here.